常用降糖药二甲双胍降低年龄相关性黄斑变性患病风险
这项回顾性病例对照研究纳入55岁以上就诊患者,按Charlson共病指数为每例AMD匹配3例对照,用单因素及条件多因素logistic回归分析。结果显示二甲双胍使用与AMD患病风险降低独立相关(OR 0.58,95%CI 0.43–0.79),其他受评估药物无此关联。
要点
- 二甲双胍使用与AMD患病风险降低独立相关,OR 0.58(95%CI 0.43–0.79)。
- 其他受评估药物未显示与AMD患病风险降低相关。
- 结果为回顾性关联,尚需前瞻性临床试验验证保护作用。
核心结论
- 服用二甲双胍的患者患AMD的风险降低,提示二甲双胍可能在AMD发生或进展中具有治疗作用。
- 作者建议进一步开展临床试验,前瞻性研究二甲双胍对AMD高危人群是否具有保护作用。
研究设计与样本
- 回顾性病例对照研究,使用佛罗里达大学健康诊所55岁以上就诊患者的病历资料。
- 每例AMD病例按Charlson共病指数匹配3例对照,以确保基线整体健康状况可比。
- AMD依据国际疾病分类第九版编码定义,采用单因素及条件多因素logistic回归分析。
主要发现
- 二甲双胍使用与AMD患病风险降低相关,且独立于其他受评估协变量,OR 0.58(95%CI 0.43–0.79)。
- 其他受评估药物与AMD患病风险降低无关联。
关键数值与推荐
- 二甲双胍使用与AMD患病风险降低相关,OR 0.58(95%CI 0.43–0.79)。
临床怎么用
- 对于有AMD风险且正在使用二甲双胍的患者,该关联可作为风险沟通的参考,但不能据此改变用药指征。
- 二甲双胍对AMD的保护作用尚未经前瞻性临床试验证实,不宜据此启动二甲双胍用于AMD预防。
局限性
- 研究为回顾性病例对照设计,无法确立因果关系。
- 原文未报告样本量、随访时长及具体混杂因素调整列表。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: AMD is the leading cause of irreversible blindness in older individuals in the Western world, and there are currently no therapies to halt disease progression. Studies suggest that the commonly prescribed antidiabetic drug, metformin, is associated with decreased risk of several ocular diseases, but no work has investigated the effect of metformin use on development of AMD. Thus, we aim to investigate whether metformin use is associated with decreased risk of developing AMD. METHODS: In this retrospective case-control study, we used medical records from patients older than 55 who have visited a University of Florida health clinic. Three controls were matched for every AMD case, defined by International Classification of Diseases, Ninth Revision code, based on the Charlson Comorbidity Index to ensure comparable baseline overall health status. Univariate and conditional multivariable logistic regressions were used to determine the association between a variety of covariates, including metformin use, and AMD diagnosis. RESULTS: Metformin use was associated with decreased odds of developing AMD, independently of the other covariates investigated, with an odds ratio of 0.58 and a 95% confidence interval of 0.43 to 0.79. Other medications assessed were not associated with decreased odds of developing AMD. CONCLUSIONS: Patients who had taken metformin had decreased odds of developing AMD, suggesting that metformin may have a therapeutic role in AMD development or progression in those who are at risk. Further work should include clinical trials to investigate prospectively whether metformin has a protective effect in those at risk for developing AMD.
引用
- Brown EE, Ball JD, Chen Z, et al. The Common Antidiabetic Drug Metformin Reduces Odds of Developing Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2019. PMID: 30973575. doi:10.1167/iovs.18-26422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。